Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
Total Valuation
Adverum Biotechnologies has a market cap or net worth of $51.60M. The enterprise value is $93.00M.
Market Cap$51.60M
Enterprise Value$93.00M
Share Statistics
Adverum Biotechnologies has 20,984,161 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,984,161
Owned by Insiders22.11%
Owned by Institutions0.40%
Financial Efficiency
Adverum Biotechnologies’s return on equity (ROE) is -1.85 and return on invested capital (ROIC) is -94.19%.
Return on Equity (ROE)-1.85
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-94.19%
Return on Capital Employed (ROCE)-0.98
Revenue Per Employee6.45K
Profits Per Employee-844.69K
Employee Count155
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Adverum Biotechnologies is ―. Adverum Biotechnologies’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.31
Price to FCF―
Price to Operating Cash Flow-0.43
PEG Ratio―
Income Statement
In the last 12 months, Adverum Biotechnologies had revenue of 1.00M and earned -130.93M in profits. Earnings per share was -6.62.
Revenue1.00M
Gross Profit-2.65M
Operating Income-153.16M
Pretax Income-130.93M
Net Income-130.93M
EBITDA-127.27M
Earnings Per Share (EPS)-6.62
Cash Flow
In the last 12 months, operating cash flow was -130.91M and capital expenditures -622.00K, giving a free cash flow of -131.53M billion.
Operating Cash Flow-130.91M
Free Cash Flow-131.53M
Free Cash Flow per Share-6.27
Dividends & Yields
Adverum Biotechnologies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change-59.38%
50-Day Moving Average2.51
200-Day Moving Average4.11
Relative Strength Index (RSI)55.85
Average Volume (3m)113.81K
Important Dates
Adverum Biotechnologies upcoming earnings date is Nov 6, 2025, TBA (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
Adverum Biotechnologies as a current ratio of 5.73, with Debt / Equity ratio of -456.11%
Current Ratio5.73
Quick Ratio5.73
Debt to Market Cap0.93
Net Debt to EBITDA-0.24
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Adverum Biotechnologies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Adverum Biotechnologies EV to EBITDA ratio is -0.97, with an EV/FCF ratio of -1.33.
EV to Sales123.43
EV to EBITDA-0.97
EV to Free Cash Flow-1.33
EV to Operating Cash Flow-1.33
Balance Sheet
Adverum Biotechnologies has $44.40M in cash and marketable securities with $92.22M in debt, giving a net cash position of $47.82M billion.
Cash & Marketable Securities$44.40M
Total Debt$92.22M
Net Cash$47.82M
Net Cash Per Share$2.28
Tangible Book Value Per Share$3.57
Margins
Gross margin is -1175.10%, with operating margin of -15315.90%, and net profit margin of -13092.70%.
Gross Margin-1175.10%
Operating Margin-15315.90%
Pretax Margin-13092.70%
Net Profit Margin-13092.70%
EBITDA Margin-12727.40%
EBIT Margin-13092.70%
Analyst Forecast
The average price target for Adverum Biotechnologies is $14.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$14.83
Price Target Upside457.52% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast1.80%